The STEP 4 trial made it clear: patients who stopped semaglutide after one year regained approximately two-thirds of their lost weight within the following year. The SURMOUNT-4 trial showed similar results for tirzepatide. These findings do not mean GLP-1 medications are not worth taking — they tell us something important about the nature of obesity and weight maintenance that every patient should understand before starting treatment.
Why Weight Regain Happens
Obesity is a chronic, biological condition — not a temporary problem with a fixed endpoint. The hormones and neurological pathways that drive food noise, appetite dysregulation, and energy storage do not permanently reset after weight loss. When GLP-1 medications are discontinued, those biological signals largely return — and so does the hunger, food noise, and appetite that made weight management difficult in the first place.
This is analogous to stopping blood pressure medication — blood pressure typically returns. The medication was managing the underlying biology, not curing it. For many patients, GLP-1 medications are most appropriately considered long-term or indefinite treatment — exactly as statins or antihypertensives are.
That said, patients who use the treatment window wisely — building habits, preserving muscle, resetting their relationship with food — have meaningfully better maintenance outcomes than those who treat the medication as a passive weight loss solution.
What Determines Long-Term Success
- Muscle Preservation During Treatment
Patients who maintain or build muscle while losing weight on GLP-1 medications have a higher resting metabolic rate, which supports weight maintenance after stopping medication. This is the most mechanically important variable for long-term maintenance.
- Habits Built, Not Just Weight Lost
GLP-1 medications create an extraordinary window to build new patterns with food — smaller portions, mindful eating, reduced reactivity to cravings — without the constant hunger that makes these habits impossible off medication. Patients who consciously build these habits during treatment carry something durable forward.
- Continued Exercise
Exercise is perhaps the strongest predictor of long-term weight maintenance in the research literature. Patients who maintain a regular resistance training practice after stopping GLP-1 medications maintain significantly more of their weight loss than sedentary patients.
- Long-Term or Maintenance Dosing
For many patients, the most evidence-based approach is not stopping medication but transitioning to a lower maintenance dose that sustains metabolic benefit while reducing cost. Your provider can discuss whether this is appropriate for your situation.
If You Are Considering Stopping: Do This First
Before stopping GLP-1 medications, discuss your plan with your provider. An abrupt discontinuation without a transition plan is the most common cause of rapid weight regain. Your provider may recommend:
- A gradual dose reduction to test your response at lower doses before fully stopping
- A longer maintenance period at your current dose before attempting discontinuation
- Specific protein and exercise targets to establish before stopping
- A clear plan for monitoring weight and metabolic markers after stopping
- A defined threshold (e.g., a specific amount of regain) that would prompt restarting medication